Principal Director, Surgical Oncology, BLK-Max Super Speciality Hospital, New Delhi
Series overview · 9 articles
Breast Cancer Diagnosis and Surgical Management
September 21, 2025
Early diagnosis is the single biggest lever for curing breast cancer, and getting the diagnostic sequence right, imaging before biopsy, the correct imaging modality for the patient's age, and a true-cut biopsy rather than a fine needle aspiration, sets up everything that follows. Dr. Rajesh Kumar Jain, Principal Director, Surgical Oncology at BLK-Max Super Speciality Hospital, New Delhi, with 26 years in the field, used his Jivo Masterclass to walk through the full pathway from a patient's first lump to long-term survivorship. This guide introduces a series based on that session.
A practical, decision-focused approach
Dr. Jain built his session around the actual decision points a referring doctor faces: which imaging to order and when, when a biopsy is mandatory versus optional, how to stage a patient without access to a PET scan, which patients can avoid mastectomy, and which can avoid chemotherapy altogether. His guidance throughout was calibrated for doctors in resource-constrained settings, offering a practical fallback at every step where the ideal test may not be locally available.
What this series covers
This series works through how a breast lump is diagnosed and imaged, the BI-RADS system for reading mammograms and ultrasounds, how breast cancer is staged including in settings without PET CT, how to choose between breast conservation and mastectomy, how the axilla is managed including the LYMPHA technique to prevent lymphoedema, when chemotherapy can be avoided using genomic risk-stratification tests, who needs BRCA testing and bilateral surgery, breast reconstruction options, and what rehabilitation and long-term survivorship actually involve.
This article is based on a Jivo Masterclass session conducted by Dr. Rajesh Kumar Jain, Principal Director, Surgical Oncology, BLK-Max Super Speciality Hospital, New Delhi. The article has been summarised with the assistance of an AI tool from the original masterclass recording. Watch the full Masterclass recording
Looking for a breast cancer or surgical oncology consultation or a second opinion? Get in touch with the Jivo team
This guide is based on a live Jivo Masterclass — Dr. Rajesh Kumar Jain taught doctors across Africa on September 21, 2025.
Watch the full recording, or read the guide above.
FROM THE LIVE Q&A
Jivo Doctor Partner (name unclear from transcript)
Is it possible to start chemotherapy in the patient's home country before sending them for further evaluation and management?
Dr. Rajesh Kumar Jain
Neoadjuvant chemotherapy should be started before referral in two situations: triple-negative breast cancer, and locally advanced disease, meaning a tumour over 5 cm, ulceration, peau d'orange skin change, satellite nodules, or bulky or supraclavicular nodes. In locally advanced disease, surgery follows after around four to four and a half months of chemotherapy. In genuinely advanced or metastatic disease, treatment is systemic only, chemotherapy or hormone therapy, with no surgery. For anything in between, it is always better to discuss the specific case jointly before deciding independently whether and when to start treatment.
Book a Consultation with Dr. Rajesh Kumar Jain
Book on WhatsAppOr message us on WhatsApp: +91 98182 98669
Frequently Asked Questions
If it is familial, should bilateral surgery be done without any further testing?▼
No, a BRCA1 and BRCA2 test should be done first. Indications for testing are all triple-negative breast cancer, a strong first-degree family history (a sister, mother, or maternal or paternal aunt with breast cancer), and any history of male breast cancer in the family, which alone is enough to warrant testing. If the BRCA test comes back positive, mastectomy of the affected breast should be combined with prophylactic mastectomy of the opposite side. If BRCA testing isn't available locally, it can be arranged through Dr. Jain's centre.
What is the definitive treatment for breast cancer?▼
There is no single definitive treatment; breast cancer, like all solid tumours, requires multimodal treatment. Chemotherapy alone, radiotherapy alone, or hormone therapy alone cannot cure it. Surgery has to be part of the treatment plan for a cure, combined with hormone therapy, chemotherapy or radiation as indicated, though surgery alone is occasionally sufficient in very select cases.
Is rehabilitative management necessary after breast cancer treatment?▼
It's mandatory, and Dr. Jain considers it roughly 95% of overall cancer management. Physical rehabilitation covers arm exercises and lifelong protection of the affected arm, no rings, blood pressure cuffs or needles on that side. Psychological rehabilitation matters just as much, since patients carry real emotional weight after a cancer diagnosis, and in some settings social rehabilitation is needed too, since patients can lose their jobs, or in some communities face marital breakdown, because of the diagnosis.
What is the prognosis for breast cancer treatment?▼
Prognosis is improving steadily. Five-year survival is around 97-98% for stage one, 90-95% for stage two, 80-85% for stage three, and even stage four disease has a 25-30% five-year survival rate. Triple-negative and locally advanced cases carry a higher recurrence risk specifically, so they need especially stringent follow-up to catch any recurrence early enough to treat.
What is the cost implication of breast cancer treatment?▼
Surgery alone, all-inclusive, costs roughly $5,000. Chemotherapy adds around $10,000, and radiation is roughly $3,500 to $4,000. Extended targeted therapy such as trastuzumab can add another $10,000, though that portion can often be continued at the patient's home location. As a rough guide, surgery plus basic chemotherapy runs around $15,000 for most patients, and cases involving genuine financial hardship can always be discussed.
What does this masterclass series on breast cancer cover?▼
The full pathway from diagnosis and imaging, staging, surgical decision-making (breast conservation versus mastectomy), axillary management, adjuvant therapy decisions including when chemotherapy can be avoided, BRCA testing, reconstruction, and rehabilitation.
Who is Dr. Rajesh Kumar Jain?▼
Principal Director, Surgical Oncology at BLK-Max Super Speciality Hospital, New Delhi, with 26 years of experience across breast, head and neck, gynaecological, soft tissue, uro-oncological and GI cancer surgery.
In This Series: Breast Cancer - Diagnosis and Surgical Management
- 1.Breast Cancer Diagnosis and Surgical Management
- 2.Diagnosing a Breast Lump: Imaging Sequence, BI-RADS and When to Biopsy
- 3.Staging Breast Cancer, Including in Settings Without PET CT
- 4.Breast Conservation Surgery vs Mastectomy: How the Decision Is Made
- 5.Axillary Management in Breast Cancer: Sentinel Biopsy and the LYMPHA Technique
- 6.When Chemotherapy Can Be Avoided: Genomic Risk-Stratification in Early Breast Cancer
- 7.BRCA Testing in Breast Cancer: Who Needs It and What Positive Results Mean
- 8.Breast Reconstruction After Mastectomy: Options and Timing
- 9.Rehabilitation and Prognosis After Breast Cancer Treatment